GW prepares for acquisition approaches
GW Pharmaceuticals is reportedly preparing itself for takeover approaches as its attractiveness continues to grow with the increasing potential of its cannabinoid portfolio.
Read More
Tag: cannidiol
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
